Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CFSAN Supplement "Disease Claims" Enforcement Authority Spelled Out

This article was originally published in The Tan Sheet

Executive Summary

FDA's Center for Food Safety & Applied Nutrition has lead responsibility for issuing warning letter drug charges for dietary supplements bearing "disease claims," under an April 6 intercenter agreement with the Center for Drug Evaluation & Research.

You may also be interested in...

Cholestin Red Yeast Rice Shipments Halted Pending FDA Talks

Pharmanex suspended U.S. shipments of Cholestin April 2 following a federal court decision affirming FDA's determination that the red yeast rice product is a drug, not a dietary supplement.

Dietary Supplement Enforcement Procedure Streamlining Planned By CFSAN

Consolidating FDA's enforcement process with regard to inappropriate dietary supplement claims is one of the Center for Food Safety & Applied Nutrition's "A-list" goals for 2000.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts